FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385186737> ?p ?o ?g. }

• W4385186737 endingPage "2102" @default.
• W4385186737 startingPage "2087" @default.
• W4385186737 abstract "Azvudine and nirmatrelvir-ritonavir are more extensively used to treat COVID-19 in China due to their earlier approval by the National Medical Products Administration. However, there has been a scarcity of research directly comparing the clinical outcomes between azvudine and nirmatrelvir-ritonavir till now. We aimed to make a head-to-head comparison of the efficacy and safety of azvudine or nirmatrelvir-ritonavir in hospitalized patients with COVID-19 in China. This retrospective cohort study was conducted using data collected from Tongde Hospital of Zhejiang Province between December 2022 and January 2023. All-cause mortality, risk of progressing to a critical condition, proportion with nucleic-acid negative conversion (PNANC), time to first nucleic-acid negative conversion (TFNANC), length of hospital stay and incidence of adverse events were systematically assessed as outcomes. Multi-model regression analysis, propensity-score-matching analysis, subgroup analysis and several sensitivity analyses were applied to compare these outcomes. This study included a total of 1571 hospitalized patients with COVID-19, among whom 272 received nirmatrelvir-ritonavir and 156 received azvudine. We found no significant differences in all-cause mortality (HR 1.41; 95% CI 0.56–3.56; P = 0.471), risk of progressing to critical COVID-19 (HR 1.67; 95% CI 0.78–3.60; P = 0.189), PNANC (HR 0.87; 95% CI 0.69–1.09; P = 0.220), length of stay (β − 0.82; 95% CI − 2.78 to 1.15; P = 0.414) and adverse event rate (3.21% vs. 4.41%, P = 0.538) between the two groups, although azvudine was slightly less effective than nirmatrelvir-ritonavir. Meanwhile, the azvudine group exhibited a significantly longer TFNANC (β 2.53; 95% CI 0.76–4.29; P = 0.005) than the nirmatrelvir-ritonavir group. Results were similar for propensity-score matching and multiple sensitivity analyses. Azvudine probably possessed comparable efficacy and safety to nirmatrelvir-ritonavir, although it was less effective than nirmatrelvir-ritonavir for some outcomes." @default.
• W4385186737 created "2023-07-25" @default.
• W4385186737 creator A5003598796 @default.
• W4385186737 creator A5003743565 @default.
• W4385186737 creator A5003879043 @default.
• W4385186737 creator A5004217020 @default.
• W4385186737 creator A5008121194 @default.
• W4385186737 creator A5008886362 @default.
• W4385186737 creator A5017416817 @default.
• W4385186737 creator A5025033156 @default.
• W4385186737 creator A5032402479 @default.
• W4385186737 creator A5037129243 @default.
• W4385186737 creator A5046922983 @default.
• W4385186737 creator A5047020466 @default.
• W4385186737 creator A5055298034 @default.
• W4385186737 creator A5059312437 @default.
• W4385186737 creator A5059959892 @default.
• W4385186737 creator A5076271299 @default.
• W4385186737 creator A5076601235 @default.
• W4385186737 creator A5092527579 @default.
• W4385186737 date "2023-07-24" @default.
• W4385186737 modified "2023-10-15" @default.
• W4385186737 title "Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study" @default.
• W4385186737 cites W3003704241 @default.
• W4385186737 cites W3023346879 @default.
• W4385186737 cites W3043552482 @default.
• W4385186737 cites W4210328896 @default.
• W4385186737 cites W4220807057 @default.
• W4385186737 cites W4223443877 @default.
• W4385186737 cites W4225691034 @default.
• W4385186737 cites W4226236384 @default.
• W4385186737 cites W4281988270 @default.
• W4385186737 cites W4287009113 @default.
• W4385186737 cites W4292457905 @default.
• W4385186737 cites W4293198902 @default.
• W4385186737 cites W4295066913 @default.
• W4385186737 cites W4298326470 @default.
• W4385186737 cites W4301393853 @default.
• W4385186737 cites W4303423758 @default.
• W4385186737 cites W4306673647 @default.
• W4385186737 cites W4309604538 @default.
• W4385186737 cites W4310130637 @default.
• W4385186737 cites W4313236293 @default.
• W4385186737 cites W4313644753 @default.
• W4385186737 cites W4317781399 @default.
• W4385186737 cites W4319322444 @default.
• W4385186737 cites W4324147991 @default.
• W4385186737 cites W4361264897 @default.
• W4385186737 cites W4366993457 @default.
• W4385186737 cites W4372279193 @default.
• W4385186737 cites W4378471640 @default.
• W4385186737 cites W4386130776 @default.
• W4385186737 cites W4386318965 @default.
• W4385186737 cites W4386359198 @default.
• W4385186737 doi "https://doi.org/10.1007/s40121-023-00845-7" @default.
• W4385186737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37486556" @default.
• W4385186737 hasPublicationYear "2023" @default.
• W4385186737 type Work @default.
• W4385186737 citedByCount "0" @default.
• W4385186737 crossrefType "journal-article" @default.
• W4385186737 hasAuthorship W4385186737A5003598796 @default.
• W4385186737 hasAuthorship W4385186737A5003743565 @default.
• W4385186737 hasAuthorship W4385186737A5003879043 @default.
• W4385186737 hasAuthorship W4385186737A5004217020 @default.
• W4385186737 hasAuthorship W4385186737A5008121194 @default.
• W4385186737 hasAuthorship W4385186737A5008886362 @default.
• W4385186737 hasAuthorship W4385186737A5017416817 @default.
• W4385186737 hasAuthorship W4385186737A5025033156 @default.
• W4385186737 hasAuthorship W4385186737A5032402479 @default.
• W4385186737 hasAuthorship W4385186737A5037129243 @default.
• W4385186737 hasAuthorship W4385186737A5046922983 @default.
• W4385186737 hasAuthorship W4385186737A5047020466 @default.
• W4385186737 hasAuthorship W4385186737A5055298034 @default.
• W4385186737 hasAuthorship W4385186737A5059312437 @default.
• W4385186737 hasAuthorship W4385186737A5059959892 @default.
• W4385186737 hasAuthorship W4385186737A5076271299 @default.
• W4385186737 hasAuthorship W4385186737A5076601235 @default.
• W4385186737 hasAuthorship W4385186737A5092527579 @default.
• W4385186737 hasBestOaLocation W43851867371 @default.
• W4385186737 hasConcept C120665830 @default.
• W4385186737 hasConcept C121332964 @default.
• W4385186737 hasConcept C126322002 @default.
• W4385186737 hasConcept C142462285 @default.
• W4385186737 hasConcept C159047783 @default.
• W4385186737 hasConcept C167135981 @default.
• W4385186737 hasConcept C17923572 @default.
• W4385186737 hasConcept C197934379 @default.
• W4385186737 hasConcept C201903717 @default.
• W4385186737 hasConcept C2779134260 @default.
• W4385186737 hasConcept C2779298103 @default.
• W4385186737 hasConcept C2993143319 @default.
• W4385186737 hasConcept C3008058167 @default.
• W4385186737 hasConcept C3013748606 @default.
• W4385186737 hasConcept C524204448 @default.
• W4385186737 hasConcept C61511704 @default.
• W4385186737 hasConcept C71924100 @default.
• W4385186737 hasConcept C72563966 @default.
• W4385186737 hasConceptScore W4385186737C120665830 @default.

• next